Like many firms in the pharmaceutical sector, Regeneron has turned a great deal of attention towards the fight against Covid-19 in recent weeks and months.

Having already entered one of its existing drug therapies into clinical studies to test its efficacy against the virus, Regeneron has also announced the start of trials for a novel antibody cocktail, which could help treat hospitalised patients, or prevent Covid-19 in uninfected people.

We take a closer look at the US biotech firm, and its ongoing attempts to uncover an effective treatment for the novel coronavirus.

Read the full article here.